Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00415-005-0934-5.

Title:
The window of therapeutic opportunity in multiple sclerosis | Journal of Neurology
Description:
From 1991–2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath–1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing–remitting (RR) and secondary progressive (SP) stages of the illness, Campath–1H reduced the annual relapse rate (from 2.2 to 0.19 and from 0.7 to 0.001 respectively; both p < 0.001). Remarkably, MRI scans of patients with SP disease, treated with Campath–1H 7 years previously, showed no new lesion formation. However, despite these effects on inflammation, disability was differently affected depending on the phase of the disease. Patients with SPMS showed sustained accumulation of disability due to uncontrolled progression marked by unrelenting cerebral atrophy, attributable to ongoing axonal loss. The rate of cerebral atrophy was greatest in patients with established cerebral atrophy and highest inflammatory lesion burden before treatment (2.3 versus 0.7 ml/year; p = 0.04). In contrast, patients with RR disease showed an impressive reduction in disability at 6 months after Campath–1H (by a mean of 1.2 EDSS points) perhaps owing to a suppression of on–going inflammation in these patients with unusually active disease. In addition, there was a further significant, albeit smaller, mean improvement in disability up to 36 months after treatment.We speculate that this represents the beneficial effects of early rescue of neurons and axons from a toxic inflammatory environment, and that prevention of demyelination will prevent long–term axonal degeneration. These concepts are currently being tested in a controlled trial comparing Campath–1H and IFN–beta in the treatment of drug–naïve patients with early, active RR MS.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

google, scholar, pubmed, cas, article, multiple, sclerosis, patients, waldmann, compston, neurol, hale, treatment, miller, brain, campathh, progressive, study, neurology, monoclonal, antibody, coles, axonal, early, therapy, clinical, disease, autoimmune, lancet, interferon, secondary, mri, disability, atrophy, ann, thompson, cerebral, smith, thyroid, effect, privacy, cookies, content, journal, degeneration, trial, access, antibodies, molyneux, filippi,

Topics {✒️}

month download article/chapter related subjects tumour necrosis factor–alpha nitric oxide–mediated degeneration intravenous dose–ranging study monoclonal antibody campath–1h macrophage–depletion induced impairment interferon–beta 1b treatment interferon beta–1b treatment ifn–beta 1b treatment serum anti–thyroid antibodies full article pdf monoclonal antibody therapy interferon beta–1a magnetic resonance imaging privacy choices/manage cookies humanised monoclonal antibody campath–1h reduced interferon beta–1b progressive cerebral atrophy campath–1h antibody unrelenting cerebral atrophy established cerebral atrophy experimental autoimmune encephalomyelitis microglial–derived tnfalpha unusually active disease progressive multiple sclerosis humanized monoclonal antibodies toxic inflammatory environment inos–mediated toxicity nmda receptor expression kaplan mr check access instant access autoimmune diseases de waegh sm definite multiple sclerosis multiple sclerosis induces acute axonal damage scope submit manuscript differently affected depending ongoing axonal loss mechanism-based criteria human hematopoietic progenitors diffuse cutaneous scleroderma experimental cns remyelination recommended diagnostic criteria mouse cerebellar neurones neuronal tract degeneration champs study group

Questions {❓}

  • Simon JH, Jacobs L, Kinkel RP (2001) Transcallosal bands: a sign of neuronal tract degeneration in early MS?
  • Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?
  • Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L (2002) Autoantibodies in multiple sclerosis patients before and during IFN–beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The window of therapeutic opportunity in multiple sclerosis
         description:From 1991–2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath–1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing–remitting (RR) and secondary progressive (SP) stages of the illness, Campath–1H reduced the annual relapse rate (from 2.2 to 0.19 and from 0.7 to 0.001 respectively; both p < 0.001). Remarkably, MRI scans of patients with SP disease, treated with Campath–1H 7 years previously, showed no new lesion formation. However, despite these effects on inflammation, disability was differently affected depending on the phase of the disease. Patients with SPMS showed sustained accumulation of disability due to uncontrolled progression marked by unrelenting cerebral atrophy, attributable to ongoing axonal loss. The rate of cerebral atrophy was greatest in patients with established cerebral atrophy and highest inflammatory lesion burden before treatment (2.3 versus 0.7 ml/year; p = 0.04). In contrast, patients with RR disease showed an impressive reduction in disability at 6 months after Campath–1H (by a mean of 1.2 EDSS points) perhaps owing to a suppression of on–going inflammation in these patients with unusually active disease. In addition, there was a further significant, albeit smaller, mean improvement in disability up to 36 months after treatment.We speculate that this represents the beneficial effects of early rescue of neurons and axons from a toxic inflammatory environment, and that prevention of demyelination will prevent long–term axonal degeneration. These concepts are currently being tested in a controlled trial comparing Campath–1H and IFN–beta in the treatment of drug–naïve patients with early, active RR MS.
         datePublished:2005-07-27T00:00:00Z
         dateModified:2005-07-27T00:00:00Z
         pageStart:98
         pageEnd:108
         sameAs:https://doi.org/10.1007/s00415-005-0934-5
         keywords:
            multiple sclerosis
            Campath–1H
            cerebral atrophy
            Neurology
            Neurosciences
            Neuroradiology
         image:
         isPartOf:
            name:Journal of Neurology
            issn:
               1432-1459
               0340-5354
            volumeNumber:253
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Steinkopff-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. J. Coles
               affiliation:
                     name:Addenbrooke’s Hospital
                     address:
                        name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:A. Cox
               affiliation:
                     name:Addenbrooke’s Hospital
                     address:
                        name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. Le Page
               affiliation:
                     name:Addenbrooke’s Hospital
                     address:
                        name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Jones
               affiliation:
                     name:Addenbrooke’s Hospital
                     address:
                        name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. A. Trip
               affiliation:
                     name:University College London
                     address:
                        name:Institute of Neurology, University College London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Deans
               affiliation:
                     name:Addenbrooke’s Hospital
                     address:
                        name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Seaman
               affiliation:
                     name:MRC Biostatistics Unit
                     address:
                        name:MRC Biostatistics Unit, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. H. Miller
               affiliation:
                     name:University College London
                     address:
                        name:Institute of Neurology, University College London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Hale
               affiliation:
                     name:University of Oxford
                     address:
                        name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. Waldmann
               affiliation:
                     name:University of Oxford
                     address:
                        name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. A. Compston
               affiliation:
                     name:Addenbrooke’s Hospital
                     address:
                        name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The window of therapeutic opportunity in multiple sclerosis
      description:From 1991–2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath–1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing–remitting (RR) and secondary progressive (SP) stages of the illness, Campath–1H reduced the annual relapse rate (from 2.2 to 0.19 and from 0.7 to 0.001 respectively; both p < 0.001). Remarkably, MRI scans of patients with SP disease, treated with Campath–1H 7 years previously, showed no new lesion formation. However, despite these effects on inflammation, disability was differently affected depending on the phase of the disease. Patients with SPMS showed sustained accumulation of disability due to uncontrolled progression marked by unrelenting cerebral atrophy, attributable to ongoing axonal loss. The rate of cerebral atrophy was greatest in patients with established cerebral atrophy and highest inflammatory lesion burden before treatment (2.3 versus 0.7 ml/year; p = 0.04). In contrast, patients with RR disease showed an impressive reduction in disability at 6 months after Campath–1H (by a mean of 1.2 EDSS points) perhaps owing to a suppression of on–going inflammation in these patients with unusually active disease. In addition, there was a further significant, albeit smaller, mean improvement in disability up to 36 months after treatment.We speculate that this represents the beneficial effects of early rescue of neurons and axons from a toxic inflammatory environment, and that prevention of demyelination will prevent long–term axonal degeneration. These concepts are currently being tested in a controlled trial comparing Campath–1H and IFN–beta in the treatment of drug–naïve patients with early, active RR MS.
      datePublished:2005-07-27T00:00:00Z
      dateModified:2005-07-27T00:00:00Z
      pageStart:98
      pageEnd:108
      sameAs:https://doi.org/10.1007/s00415-005-0934-5
      keywords:
         multiple sclerosis
         Campath–1H
         cerebral atrophy
         Neurology
         Neurosciences
         Neuroradiology
      image:
      isPartOf:
         name:Journal of Neurology
         issn:
            1432-1459
            0340-5354
         volumeNumber:253
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Steinkopff-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. J. Coles
            affiliation:
                  name:Addenbrooke’s Hospital
                  address:
                     name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:A. Cox
            affiliation:
                  name:Addenbrooke’s Hospital
                  address:
                     name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. Le Page
            affiliation:
                  name:Addenbrooke’s Hospital
                  address:
                     name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Jones
            affiliation:
                  name:Addenbrooke’s Hospital
                  address:
                     name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. A. Trip
            affiliation:
                  name:University College London
                  address:
                     name:Institute of Neurology, University College London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Deans
            affiliation:
                  name:Addenbrooke’s Hospital
                  address:
                     name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Seaman
            affiliation:
                  name:MRC Biostatistics Unit
                  address:
                     name:MRC Biostatistics Unit, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. H. Miller
            affiliation:
                  name:University College London
                  address:
                     name:Institute of Neurology, University College London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Hale
            affiliation:
                  name:University of Oxford
                  address:
                     name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. Waldmann
            affiliation:
                  name:University of Oxford
                  address:
                     name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. A. Compston
            affiliation:
                  name:Addenbrooke’s Hospital
                  address:
                     name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Neurology
      issn:
         1432-1459
         0340-5354
      volumeNumber:253
Organization:
      name:Steinkopff-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Addenbrooke’s Hospital
      address:
         name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
         type:PostalAddress
      name:Addenbrooke’s Hospital
      address:
         name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
         type:PostalAddress
      name:Addenbrooke’s Hospital
      address:
         name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
         type:PostalAddress
      name:Addenbrooke’s Hospital
      address:
         name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
         type:PostalAddress
      name:University College London
      address:
         name:Institute of Neurology, University College London, London, UK
         type:PostalAddress
      name:Addenbrooke’s Hospital
      address:
         name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
         type:PostalAddress
      name:MRC Biostatistics Unit
      address:
         name:MRC Biostatistics Unit, Cambridge, UK
         type:PostalAddress
      name:University College London
      address:
         name:Institute of Neurology, University College London, London, UK
         type:PostalAddress
      name:University of Oxford
      address:
         name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
         type:PostalAddress
      name:University of Oxford
      address:
         name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
         type:PostalAddress
      name:Addenbrooke’s Hospital
      address:
         name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. J. Coles
      affiliation:
            name:Addenbrooke’s Hospital
            address:
               name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:A. Cox
      affiliation:
            name:Addenbrooke’s Hospital
            address:
               name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
               type:PostalAddress
            type:Organization
      name:E. Le Page
      affiliation:
            name:Addenbrooke’s Hospital
            address:
               name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
               type:PostalAddress
            type:Organization
      name:J. Jones
      affiliation:
            name:Addenbrooke’s Hospital
            address:
               name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
               type:PostalAddress
            type:Organization
      name:S. A. Trip
      affiliation:
            name:University College London
            address:
               name:Institute of Neurology, University College London, London, UK
               type:PostalAddress
            type:Organization
      name:J. Deans
      affiliation:
            name:Addenbrooke’s Hospital
            address:
               name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
               type:PostalAddress
            type:Organization
      name:S. Seaman
      affiliation:
            name:MRC Biostatistics Unit
            address:
               name:MRC Biostatistics Unit, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:D. H. Miller
      affiliation:
            name:University College London
            address:
               name:Institute of Neurology, University College London, London, UK
               type:PostalAddress
            type:Organization
      name:G. Hale
      affiliation:
            name:University of Oxford
            address:
               name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      name:H. Waldmann
      affiliation:
            name:University of Oxford
            address:
               name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      name:D. A. Compston
      affiliation:
            name:Addenbrooke’s Hospital
            address:
               name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
      name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
      name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
      name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
      name:Institute of Neurology, University College London, London, UK
      name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
      name:MRC Biostatistics Unit, Cambridge, UK
      name:Institute of Neurology, University College London, London, UK
      name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
      name:Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
      name:Department of Clinical Neurosciences, Box 165, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(204)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.05s.